Description
ORY-1001 is a potent and selective inhibitor of LSD1 (IC₅₀ < 20 nM). It targets acute myeloid leukemia (AML) stem cells and significantly reduces tumor cell load while increasing survival time in mouse models of AML. ORY-1001 is in clinical trials for cancer treatment.
ORY-1001 is a potent and selective inhibitor of LSD1 (IC₅₀ < 20 nM). It targets acute myeloid leukemia (AML) stem cells and significantly reduces tumor cell load while increasing survival time in mouse models of AML. ORY-1001 is in clinical trials for cancer treatment.
Alternate Name/Synonyms: N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, dihydrochloride; RG-6016
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 1431326-61-2
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₅H₂₄Cl₂N₂
Molecular Weight: 303.27
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (~7 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent and selective LSD1 inhibitor
MDL Number: N/A
PubChem CID: 71664305
SMILES: C1CC(CCC1N)NC2CC2C3=CC=CC=C3.Cl.Cl
InChi: InChI=1S/C15H22N2.2ClH/c16-12-6-8-13(9-7-12)17-15-10-14(15)11-4-2-1-3-5-11;;/h1-5,12-15,17H,6-10,16H2;2*1H/t12?,13?,14-,15+;;/m0../s1
InChi Key: UCINOBZMLCREGM-RNNUGBGQSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |